Planned gene expression assay launches and high-multiplex capabilities are expected to expand QIAcuity into one of the largest molecular biology application areas ...
NEW YORK , June 4, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact...
Two custom-designed research-use-only (RUO) QIAcuity digital PCR assays now available to target Bundibugyo ebolavirus sequences associated with the current outbreak ...
NEW YORK , May 28, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact...
NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact...
New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface ...
Qiagen shares dropped more than 10% after the company slashed FY 2026 sales-growth guidance from "at least 5% CER" to just 1-2% CER -- erasing hundreds of millions in market capitalization in a single...
The law firm of Kirby McInerney LLP continues its investigation on behalf of Qiagen N.V. (“Qiagen” or the “Company”) (NYSE:QGEN) investors concerning the Company’s and/or members...
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases ...
NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Qiagen N.V. ("Qiagen" or the "Company") (NYSE: QGEN). Such investors are advised to contact...